Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position

2026-02-25 15:55:37 ET

On February 17, 2026, hedge fund BVF disclosed a buy of 275,105 shares of Structure Therapeutics (NASDAQ:GPCR) , with an estimated transaction value of $11.2 million based on quarterly average pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, BVF increased its position in Structure Therapeutics (NASDAQ:GPCR) by 275,105 shares. The estimated value of this purchase, based on the quarterly average share price, is $11.2 million. The fund's quarter-end position in Structure Therapeutics was valued at $242.0 million, up $152.3 million from the previous filing, a figure that accounts for both trading and price movement.

Structure Therapeutics is a clinical-stage biotechnology company specializing in the development of oral small molecule therapeutics for chronic diseases with significant unmet need. The company leverages expertise in G-protein-coupled receptor (GPCR) biology to advance a pipeline led by GSBR-1290 for type-2 diabetes and obesity, and additional candidates for pulmonary and cardiovascular disorders.

Continue reading